Nifty Pharma: The index reflects mixed performance, with top gainers like Natco Pharma and Laurus Labs. Sector growth is driven by R&D and global demand.

Pharmaceuticals reported Q3 FY25 EPS of ₹12.33, rebounding from a loss last year. Recent launches like Empagliflozin strengthen its diabetes portfolio.